Hysteria over vaping-related lung illness appeared out of nowhere and in a flash consumed the entire North American vaping industry.
It began on August 16 with a short media statement issued by the U.S. Centers for Disease Control, and by September 11, it had metastasized into a Presidential vaping ban.
Canada was not immune. The following week Dr. Christopher Mackie, medical officer for the Middlesex-London region in Ontario, held a gripping news conference to announce the first confirmed case of vaping-related lung illness in Canada. As was the case in the U.S., although, with more bravo, Dr. Mackie slow-walked the release of critical information regarding the suspect substance i.e. THC or nicotine and then refused to disclose the brand name of the product involved.
Did U.S. and Canadian health officials withhold information that could have protected the public from further exposure, illness or even death?
Find out, in this RegWatch exclusive interview with Dr. Mark Tyndall, North American expert on infectious disease and Professor of Medicine, UBC School of Population and Public Health.
Only on RegWatch, by RegulatorWatch.com
Released: October 1, 2019
Produced by: Brent Stafford
Want More Investigative Content?
